Anatomy of an FDA warning letter to a peptide supplier: unapproved new drug, misbranded, the 15-day response window, heavy evidence but not a court finding.
An FDA warning letter is the most consequential public document that attaches to a research peptide supplier, and the most misread. This guide walks through what a warning letter contains, what its two most common legal terms mean in procedural terms, how the response process works, how to find and read a letter yourself, and why we weight it heavily in our grades while refusing to describe it as a finding of wrongdoing.
What a warning letter is
The FDA issues a warning letter when it has reviewed a company’s products, labeling or website and concluded that the company appears to be violating the Federal Food, Drug, and Cosmetic Act. The letter sets out the violations the agency believes it has found, cites the statutory sections, and asks the company to respond in writing within 15 working days with the corrective actions it has taken or plans to take.
The FDA describes warning letters as informal and advisory. They are the agency’s primary way of obtaining voluntary compliance before it considers enforcement actions such as seizure of product, an injunction, or a referral for criminal prosecution. A letter is not a lawsuit, a fine, a recall order or a license revocation. It is a documented statement of the agency’s position, placed on the public record.
Anatomy of a letter
Warning letters to peptide suppliers follow a consistent structure.
| Section | What it contains | What to look for |
|---|---|---|
| Header | Date, reference number, issuing office or center, delivery method, addressee name and address | The legal entity named is the one the letter binds; compare it to the storefront’s footer |
| Opening | A statement that the FDA reviewed the company’s website on specific dates, with the URL | The dates and URL tell you which storefront and which version of it was examined |
| Products at issue | The product names the agency reviewed | Matches to the current catalog show whether the products are still listed |
| Quoted claims | Verbatim quotes from product pages, blogs or social posts that the agency says establish intended use | These are the supplier’s own words; the letter reproduces them so the conclusion can be checked |
| Legal conclusions | The sections of the Act the agency believes are violated, usually “unapproved new drug” and “misbranded” | Each conclusion is tied to a specific statutory section and to the quoted claims |
| Scope disclaimer | A statement that the letter is not an all-inclusive list of violations | The agency is telling the company to review everything, not just the examples |
| Response request | The 15-working-day window, what the response should contain, and the contact for it | The clock starts at receipt; the response, if any, is not usually published |
| Signature | The signing official and office | Identifies the center (for peptide letters, typically the Center for Drug Evaluation and Research) |
What “unapproved new drug” means
The Act defines a drug partly by intended use. A product intended to affect the structure or any function of the body, or intended for use in connection with disease, is a drug under section 201(g), whatever it is labeled. A “new drug” under section 201(p) is one not generally recognized among qualified experts as safe and effective for its labeled conditions of use. A new drug may not be introduced into interstate commerce without an approved application, under section 505(a).
The procedural logic of a peptide letter is therefore a chain: the supplier’s product pages or posts make claims about effects on the body or on disease; those claims establish intended use; intended use makes the product a drug; the product has no approved application; therefore it is an unapproved new drug, and selling it violates section 301(d) of the Act.
The research-use-only label does not break the chain. The FDA’s consistent position in these letters is that a disclaimer stating a product is for research use does not override intended use demonstrated by the company’s marketing. Our explainer on research-use-only labeling covers why a disclaimer and a health claim on the same page is a contradiction we flag.
What “misbranded” means
A drug is misbranded under section 502 if its labeling is false or misleading, or if it fails to bear adequate directions for use under section 502(f)(1). The letters typically argue that because the products are drugs whose intended uses cannot be followed safely without professional supervision, adequate directions for lay use cannot be written, and no exemption from that requirement applies. Introducing a misbranded drug into interstate commerce violates section 301(a).
In plain terms: once the agency has concluded a product is a drug, almost any consumer-facing labeling of it will also be misbranded, because the labeling cannot satisfy requirements written for approved drugs. The misbranding charge usually follows automatically from the unapproved-drug charge.
The response and what happens after
The company has 15 working days to reply. A response normally describes what has been removed from the site, what has been discontinued, and what procedures prevent recurrence. The FDA may reply, may request more, or may issue a close-out letter if it is satisfied that corrections are complete. Close-out letters are posted to the same database. If the company does not respond or the agency is not satisfied, the next steps are separate enforcement actions, each with its own record.
Nothing in that sequence is automatic. One supplier can remove the quoted claims and never hear from the agency again; another can ignore the letter and face a seizure or criminal referral years later. The letter alone does not tell you which path followed.
How to find and read a letter
- Go to the FDA’s Warning Letters page on fda.gov and use the search by company name. Try the legal entity name as well as the brand name; letters are addressed to entities, and the two often differ.
- Open the letter and read the header first: date, addressee, URL reviewed. Confirm it is the supplier you are researching and not a similarly named business.
- Read the quoted claims. These are the supplier’s own words, reproduced by the agency so the conclusion can be checked. Decide for yourself whether the quotes support the intended-use argument.
- Check whether the quoted claims are still on the supplier’s site. The Wayback Machine helps if the pages have changed.
- Search the database again for a close-out letter to the same entity.
Our supplier reports do steps 1 and 2 for you: every record with a letter shows the letter date and links the FDA page in the regulatory section.
Letters in our data set
As of October 2026, seven of the 62 suppliers we track have a warning letter on record, with issue dates of December 7, 2020, May 18, 2021, December 10, 2024 (three letters), September 8, 2025 and August 24, 2026. Three letters sharing one issue date is consistent with the agency reviewing a group of storefronts together. One of the seven suppliers later closed; its record documents a guilty plea and sentence in a separate criminal matter, which is a court outcome and distinct from the letter.
Why heavy evidence but not a court finding
We subtract a fixed penalty from the track-record factor for any supplier with a warning letter, and the letter is reported on the supplier’s page with its date and link. The weight is deliberate. A warning letter is written by a federal regulator after a documented review, cites the supplier’s own published words, and sits on the public record indefinitely. No other public document about a research peptide supplier carries that much procedural weight.
It is still not a finding of fact by a court. The company has not been tried, has had no opportunity to contest the agency’s reading before a neutral party, and may have corrected everything the letter describes within the month. We write “the FDA issued a warning letter dated X concerning Y” and we stop there. The letter says what it says; what the supplier did next is a separate question, and our reports answer it only with evidence.